Healthcare Triangle, Inc. Launches Agentic AI Agent for Healthcare Services Accessibility StatementSkip Navigation Agentic AI market is projected to expand to $200 Billion by 2034 and HCTI vision is to be part of that growth Building on Teyame's proven success in the Spanish market, HCTI is rapidly scaling these advanced capabilities across the United States and Latin America. The expansion integrates nextgeneration omnichannel automation with HCTI's deep healthcare technology expertise to deliver a modern, ...

Core Viewpoint - Healthcare Triangle, Inc. has announced a $2 million share repurchase program, reflecting the Board's commitment to prudent capital allocation and confidence in the Company's long-term strategy [1]. Group 1: Share Repurchase Program - The Board of Directors approved the 2026 Share Repurchase Plan on March 9, 2026, allowing the Company to repurchase up to $2,000,000 of its outstanding common stock [1]. - The repurchase may occur through open market transactions, privately negotiated transactions, or other means, in compliance with applicable securities laws [1]. - The timing, volume, and nature of repurchases will be determined by management based on market conditions and other factors [1]. Group 2: Implementation and Funding - The program does not obligate the Company to acquire a specific amount of shares and may be suspended, modified, or discontinued at the Company's discretion [1]. - The Company may fund repurchases using available cash and cash equivalents or other sources of liquidity [1]. - The Board authorized Company officers to take necessary actions to implement the plan, including engaging brokers and making required filings [1]. Group 3: Company Overview - Healthcare Triangle, Inc. specializes in digital transformation solutions for the healthcare and life sciences industries, including managed services, cloud enablement, and data analytics [1]. - The Company supports healthcare organizations in improving health outcomes through better utilization of data and information technologies [1]. - Healthcare Triangle has achieved HITRUST Certification for its Cloud and Data Platform, demonstrating high standards for data protection and information security [1].

Core Insights - Healthcare Triangle's subsidiary QuantumNexis Inc. has launched operations in Dubai, UAE, aiming to enhance digital health transformation across the GCC countries [1] - The launch is part of a strategic expansion to support national healthcare modernization initiatives in the UAE, Saudi Arabia, Qatar, Oman, and Bahrain [1] - QuantumNexis integrates multiple brands and partnerships, including Ezovion Health OS, Ziloy.ai, and Better.care, to deliver AI-powered healthcare solutions [1] Market Opportunity - The GCC is identified as one of the fastest-growing digital health markets globally, driven by government investments and AI adoption [1] - The digital health market in Saudi Arabia is projected to exceed USD 11 billion by 2033, while the UAE's market is expected to reach USD 1.84 billion by 2030 [1] Strategic Focus Areas - Key focus areas for QuantumNexis include regulatory compliance, workforce capability development, digital mental health solutions, AI-powered automation, and interoperability [1] - The company aims to deliver compliant and AI-native healthcare solutions tailored to regional needs [1]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - TG-17, Inc. (OBAI) has increased by 123% to $6.98 [3] - Polaryx Therapeutics, Inc. (PLYX) is up 78% at $4.29 [3] - ZIM Integrated Shipping Services Ltd. (ZIM) has risen by 34% to $29.97 [3] - Masimo Corporation (MASI) is up 33% at $173.80 [3] - Ocular Therapeutix, Inc. (OCUL) has increased by 26% to $11.21 [3] - Empery Digital Inc. (EMPD) is up 15% at $4.34 [3] - Digital Brands Group, Inc. (DBGI) has risen by 12% to $5.40 [3] - Kennedy-Wilson Holdings, Inc. (KW) is up 9% at $10.82 [3] - urban-gro, Inc. (UGRO) has increased by 8% to $3.89 [3] - Neo-Concept International Group Holdings Limited (NCI) is up 6% at $2.55 [3] Premarket Losers - JIADE Limited (JDZG) has decreased by 48% to $1.98 [4] - AIM ImmunoTech Inc. (AIM) is down 19% at $1.01 [4] - Founder Group Limited (FGL) has fallen by 16% to $15.10 [4] - Mega Fortune Company Limited (MGRT) is down 12% at $6.53 [4] - Moolec Science SA (MLEC) has decreased by 9% to $7.80 [4] - Creative Global Technology Holdings Limited (CGTL) is down 8% at $2.68 [4] - Danaher Corporation (DHR) has fallen by 7% to $196.00 [4] - Westwood Holdings Group, Inc. (WHG) is down 7% at $16.37 [4] - Psyence Biomedical Ltd. (PBM) has decreased by 6% to $2.90 [4] - Healthcare Triangle, Inc. (HCTI) is down 5% at $8.10 [4]

Core Viewpoint - Healthcare Triangle (HCTI) will implement a 1-for-60 reverse stock split to increase its share price and comply with Nasdaq's minimum bid price requirement of $1.00 [1] Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on February 10, 2026 [1] - HCTI's common stock will begin trading on a post-split basis on the Nasdaq Capital Market on the same date [1] - The reverse stock split was approved by stockholders during a special meeting held on February 2, 2026 [1] Group 2: Strategic Implications - The company anticipates that the reverse stock split will help increase the price per share of its common stock [1] - This action is part of HCTI's broader strategy to regain compliance with Nasdaq's listing requirements [1]

Core Insights - The joint venture between Healthcare Triangle's subsidiary QuantumNexis and Golden Code Holdings aims to tap into the rapidly growing $70 billion healthcare market in Saudi Arabia by 2030 [1][2]. Group 1: Joint Venture Objectives - The partnership combines QuantumNexis' expertise in AI-powered healthcare platforms with Golden Code Holdings' local market knowledge to support Saudi Vision 2030 and the Ministry of Health's digital strategy [2][5]. - The joint venture is focused on creating a data-driven healthcare ecosystem that emphasizes value-based care, prioritizing patient outcomes over service volume [2][5]. Group 2: Digital Health Solutions - QuantumNexis plans to introduce a suite of advanced digital health platforms in Saudi Arabia, aimed at modernizing workflows and improving care coordination across healthcare facilities [3][6]. - Key offerings include Ezovion for hospital operations, Ziloy.ai for clinical intelligence, and Readabl.ai for documentation automation, alongside interoperability solutions through partnerships with Better.care and Microsoft [6][7]. Group 3: Strategic Goals - The joint venture aims to drive national-scale digital health modernization, support localization and compliance, and establish a regional hub for innovation and research [7][8]. - It will also focus on building a Saudi-based digital health workforce through capability development programs [7][8]. Group 4: Market Impact - The collaboration is expected to create new opportunities for local talent and technology leadership, accelerating the transition to interoperable, data-driven healthcare in Saudi Arabia [5][9].

Core Insights - Healthcare Triangle, Inc. has entered into a Development Program Agreement with Better, a global digital healthcare platform provider, marking a significant milestone in advancing digital health innovation and expanding its presence in high-growth markets [1][2][5] Partnership Details - The agreement initiates a long-term partnership, allowing QuantumNexis and other HCTI subsidiaries to access training and certification programs to enhance their expertise and delivery capabilities using Better's platform [2][4] - This collaboration aims to transform healthcare delivery globally by combining Healthcare Triangle's innovation with Better's robust platform, focusing on patient care in emerging markets [3][5] Market Expansion - The partnership positions HCTI and QuantumNexis to pursue digital health opportunities across Europe, Southeast Asia, the Middle East, and Africa, targeting countries like India, Malaysia, Indonesia, the Philippines, Saudi Arabia, and various African markets [5][7] - Better's platform supports over 30 million patients and has provided solutions in more than 20 markets globally, emphasizing its capability to manage and exchange structured electronic health records [8] Workforce Development - The collaboration includes launching structured training and certification programs for teams at HCTI and QuantumNexis to accelerate the adoption of Better's solutions, enhancing workforce enablement [4]

Core Insights - Healthcare Triangle, Inc. (HCTI) is participating in the Deal Flow Discovery Conference on January 28-29, 2026, in Atlantic City, New Jersey, where it will present its strategic vision and growth initiatives [1][1][1] Company Overview - HCTI is a leader in digital transformation solutions for healthcare and life sciences, focusing on improving health outcomes through better utilization of data and information technologies [1][1] - The company provides HITRUST Certification for its Cloud and Data Platform, demonstrating high standards for data protection and information security [1][1] Conference Participation - At the conference, HCTI will showcase its expanding portfolio, including healthcare cloud services, AI-driven data platforms, and digital transformation solutions for hospitals and health systems [1][1] - The leadership team will discuss recent milestones and growth initiatives, including an International Acquisition Road Map and proprietary patient engagement tools [1][1] Strategic Focus - HCTI emphasizes AI-led managed services aimed at enhancing efficiency, cost optimization, and business agility in the highly regulated healthcare and life sciences industries [1][1] - The company is focused on cybersecurity and compliance solutions, behavioral healthcare solutions in EMEA, and digital-first healthcare solutions for providers [1][1]

Core Viewpoint - Healthcare Triangle, Inc. (HCTI) is acquiring Teyame AI LLC and its subsidiaries, enhancing its position in AI-powered customer and patient engagement solutions, with a total consideration of approximately $50 million [1][2]. Financial Impact - The acquired assets generated approximately $32 million in incremental annual revenue and about $3.6 million in incremental EBITDA for fiscal year 2025, indicating a significant potential for enhancing HCTI's financial performance and shareholder value [2]. Strategic Importance - This acquisition marks a pivotal moment in HCTI's transition from a healthcare IT provider to a comprehensive digital innovator, aiming to create an integrated ecosystem that personalizes patient interactions [5][4]. Technological Integration - The integration of AI-powered engagement platforms with HCTI's healthcare technologies is expected to deliver a next-generation intelligent ecosystem for patients and providers, expanding HCTI's SaaS footprint into Europe and Latin America [4][5]. Innovation and Capabilities - The assets include advanced technologies such as chatbot automation, multilingual patient engagement tools, and real-time analytics, which will enhance HCTI's clinical systems and overall service offerings [8][11].

Core Insights - Healthcare and biotechnology stocks experienced significant movements in after-hours trading, with several companies showing strong gains despite limited news flow [1] Company Summaries - Novo Nordisk A/S (NVO) saw a notable increase of 9.48%, closing at $52.66, following FDA approval of its Wegovy pill, the first oral GLP-1 medicine for obesity in the U.S., which is also approved to reduce cardiovascular risks [2] - Neumora Therapeutics, Inc. (NMRA) advanced 16.02% to $2.10, indicating investor interest possibly driven by broader sector momentum or speculative trading, as there were no specific news updates [3] - BioRestorative Therapies, Inc. (BRTX) rose 6.90% to $1.24, with investors reacting to a prior announcement regarding an FDA Type B meeting to discuss a potential accelerated BLA pathway for its BRTX-100 program for chronic lumbar disc disease [4] - RenovoRx, Inc. (RNXT) added 4.44% to close at $0.94, with earlier news of an accepted abstract submission for the ASCO Gastrointestinal Cancers Symposium 2026 contributing to investor interest [5] - IDEAYA Biosciences, Inc. (IDYA) gained 6.49% to $37.81, following the full enrollment of 435 patients in its Phase 2/3 trial for darovasertib, with expected data reporting in Q1 2026 [6] - Healthcare Triangle, Inc. (HCTI) climbed 6.72% to $1.43, with a recent announcement of an Advance Agreement for acquiring AI-powered customer experience firms, enhancing its position in global AI-driven solutions [7] - Alphatec Holdings, Inc. (ATEC) posted a modest gain of 2.80%, rising to $21.28, benefiting from ongoing investor confidence in the spine surgery provider [8]